ABSTRACTACAC hemoperfusion was used in series with a small fluid removal system for a clinical trial in the treatment of uremia. A 22‐month trial included a pretest control period, test period and a post‐test control period. The most significant observations from this trial are: 1) the predialysis body weight of the patient could be maintained closer to the patient's dry weight; 2) there was a significant increase in hematocrit; and 3) there was insufficient removal of urea. With the development of an effective urea removal system, a more compact artificial kidney than any presently available will become feasi
展开▼
